Tourette syndrome
is a neurological disorder characterized by repetitive, involuntary movements and vocalizations known as tics. While there is no cure for Tourette syndrome, treatment options can help manage symptoms. Treatment can include medications, such as antipsychotics, alpha-2 adrenergic agonists, and dopamine-depleting agents, which can help reduce tics. Behavioral therapy, such as cognitive-behavioral therapy and habit reversal training, can also be used to help manage tics and improve social functioning. In severe cases, deep brain stimulation surgery may be considered. The Tourette Syndrome Association of America recommends an individualized approach to treatment, as symptoms can vary widely among individuals. As such, a combination of medication and behavioral therapy tailored to the individual is often used.
Major Players in the Tourette syndrome Industry:
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc. is a biopharmaceutical company that was founded in 1992 and is headquartered in San Diego, California. The company specializes in discovering and developing drugs for neurological and endocrine-related diseases. In March 2023, the company announced that it had received FDA approval for its drug, Ingrezza, for the treatment of Tourette syndrome. The company operates in the United States and Europe.
Novartis AG
Novartis AG is a Swiss multinational pharmaceutical company that was founded in 1996 and is headquartered in Basel, Switzerland. The company specializes in researching, developing, and marketing pharmaceutical drugs for various diseases. In November 2021, the company announced that it had received FDA approval for its drug, Adakveo, for the treatment of Tourette syndrome. Novartis operates in more than 140 countries worldwide.
Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company that was founded in 1964 and is headquartered in Tokyo, Japan. The company focuses on developing and marketing drugs for various therapeutic areas such as CNS disorders, oncology, and cardiovascular diseases. The company's Tourette syndrome drug, Abilify, was approved by the FDA in 2009. Otsuka operates in Asia, Europe, and the United States.
Apotex, Inc.
Apotex, Inc. is a Canadian pharmaceutical company that was founded in 1974 and is headquartered in Toronto, Canada. The company specializes in developing and manufacturing generic pharmaceuticals. In January 2023, the company announced that it had received FDA approval for its generic version of Ingrezza, which is used to treat Tourette syndrome. The company operates in over 45 countries worldwide.